Status:
NOT_YET_RECRUITING
Secondary Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for PARP Inhibitors Resistance Patients
Lead Sponsor:
Fudan University
Conditions:
Ovarian Cancer
Eligibility:
FEMALE
18+ years
Phase:
PHASE2
Brief Summary
At present, the treatment of recurrent ovarian cancer after PARP inhibitor therapy is quite challenging, and there is no research on the application of hyperthermic intraperitoneal chemotherapy(HIPEC)...
Detailed Description
1. Overall design This is a single-center, prospective, single-arm, phase II clinical trial to evaluate the safety and efficacy of decellularization combined with intraperitoneal hyperthermic perfusio...
Eligibility Criteria
Inclusion
- Patients with previously diagnosed ovarian cancer, fallopian tube cancer, or primary peritoneal cancer;
- Maintain treatment with PARP inhibitors before recurrence;
- The imaging assessment is suitable, and the patient agrees to undergo further cytoreductive surgery;
- The outcome of recurrent surgery is R0 or R1 resection;
- Sign the informed consent form;
- Age≥18 years old;
Exclusion
- Patients with ovarian cancer excluded by pathological or clinical diagnosis;
- Inappropriate imaging evaluation or physical intolerance for surgical patients;
- Isolated lymph node recurrence
- Patients who undergo unsatisfactory tumor reduction surgery (R2 resection) due to recurrence;
- Patients who are unwilling to participate in the clinical trial.
Key Trial Info
Start Date :
August 31 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
94 Patients enrolled
Trial Details
Trial ID
NCT06544460
Start Date
August 31 2024
End Date
December 31 2026
Last Update
August 9 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fudan university shanghai cancer center, Deparment of gynecologic oncology
Shanghai, Shanghai Municipality, China, 200032